The senators — consisting of 19 democrats and independent Sen. Bernie Sanders (Vt.) —sent a letter Tuesday to Helen Bresch, CEO of Canonsburg, Pa.-based Mylan. The senators called the move “a well-defined industry tactic to keep costs high through a complex shell game.”
In the letter, the senators described the company’s discount program as “short-term co-pay assistance for expensive drugs,” and observed that “insurance companies, the government and employers still bear the burden of these excessive prices,” according to the report.
The senators added these higher insurance and government costs “areeventually passed on to consumers in the form of higher premiums.”
More articles on supply chain:
FDA approves new flu vaccine
The rise of the unbranded drug ad: 5 things to know
FDA fast tracks experimental drug to treat Parkinson’s
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
